BBOT (BridgeBio Oncology Therapeutics) ROCE %: -46.90% (As of Mar. 2026)


BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.40
View Full Analysis

What is BridgeBio Oncology Therapeutics ROCE %?

BridgeBio Oncology Therapeutics BBOT +3.70% 12 ROCE % is -46.90% as of Mar. 2026. GuruFocus rates BBOT with a GF Score™ of 12/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BridgeBio Oncology Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -46.90%.

BridgeBio Oncology Therapeutics  (NAS:BBOT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BridgeBio Oncology Therapeutics ROCE % Related Terms

BridgeBio Oncology Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for BridgeBio Oncology Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Oncology Therapeutics ROCE % Chart

BridgeBio Oncology Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
ROCE %
0.00 -120.79 -52.26

BridgeBio Oncology Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only -68.43 -96.38 -68.65 -40.27 -46.90
BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics ROCE % Calculation

BridgeBio Oncology Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-145.819/( ( (164.301 - 19.58) + (448.381 - 35.041) )/ 2 )
=-145.819/( (144.721+413.34)/ 2 )
=-145.819/279.0305
=-52.26 %

BridgeBio Oncology Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-184.716/( ( (448.381 - 35.041) + (417.646 - 43.26) )/ 2 )
=-184.716/( ( 413.34 + 374.386 )/ 2 )
=-184.716/393.863
=-46.90 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -46.90% mean?
BridgeBio Oncology Therapeutics (BBOT) has a ROCE % of -46.90% as of Mar. 2026.
Is BridgeBio Oncology Therapeutics' ROCE % too high?
BridgeBio Oncology Therapeutics' current ROCE % is -46.90%. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' ROCE % compare to FTH and MNPR?
BridgeBio Oncology Therapeutics' ROCE % of -46.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. BridgeBio Oncology Therapeutics's current ROCE % is -46.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current ROCE % of -46.90%. The current ROCE % is -46.90%. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current ROCE % is -46.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.40
Price